<DOC>
	<DOCNO>NCT02418585</DOCNO>
	<brief_summary>The purpose study compare efficacy safety switch treatment-resistant depression ( TRD ) subject prior antidepressant treatment ( respond ) either intranasal esketamine plus new oral antidepressant switch new oral antidepressant plus intranasal placebo .</brief_summary>
	<brief_title>A Study Evaluate Efficacy , Safety , Tolerability Flexible Doses Intranasal Esketamine Plus Oral Antidepressant Adult Participants With Treatment-resistant Depression</brief_title>
	<detailed_description>This randomize , double-blind ( neither researcher subject know treatment subject receiving ) , active-controlled , multicenter study ( 1 study site ) subject TRD ass efficacy , safety , tolerability flexible dos intranasal esketamine plus newly initiate oral antidepressant compare newly initiate oral antidepressant ( active comparator ) plus intranasal placebo . The study consist 3 phase : Screening/Prospective Observational Phase ( 4-7 week ) , Double-blind Induction Phase ( 4-weeks ) , Follow-up Phase ( 24-weeks ) . Subjects rollover long-term maintenance study participate Follow-up Phase . The antidepressant treatment , well ongoing medication take depression screen ( include adjunctive/ augmentation therapy ) , continue unchanged , dosage , start Week 1 end Week 4 screening/prospective observational phase . Subjects ' safety monitor throughout study .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Treatment-Resistant</mesh_term>
	<mesh_term>Venlafaxine Hydrochloride</mesh_term>
	<mesh_term>Duloxetine Hydrochloride</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Sertraline</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>At time sign informed consent form ( ICF ) , participant must man woman 18 ( old minimum legal age consent country study take place great [ &gt; ] 18 ) 64 year age , inclusive At start screening/prospective observational phase , participant must meet Diagnostic Statistical Manual Mental Disorders ( DSM5 ) diagnostic criterion singleepisode major depressive disorder ( MDD ) ( singleepisode MDD , duration must great equal [ &gt; = ] 2 year ) recurrent MDD , without psychotic feature , base upon clinical assessment confirm MiniInternational Neuropsychiatric Interview ( MINI ) At start screening/prospective observational phase , participant must Inventory Depressive SymptomatologyClinician rat ( IDSC30 ) total score great equal ( &gt; = ) 34 At start screening/prospective observational phase , participant must nonresponse ( great equal [ &lt; =25 ] percent [ % ] improvement ) â‰¥1 less equal ( &lt; = ) 5 ( current episode &gt; 2 year , upper limit applicable last 2 year ) oral antidepressant treatment current episode depression , assess use Massachusetts General Hospital Antidepressant Treatment Response Questionnaire ( MGHATRQ ) document medical history pharmacy/prescription record , current episode depression . In addition , participant take different oral antidepressant treatment ( MGHATRQ ) least previous 2 week minimum therapeutic dose The participant 's current major depressive episode , depression symptom severity ( Week 1 MADRS total score &gt; =28 require ) , antidepressant treatment response current depressive episode , must confirm use Site Independent Qualification Assessment Participants previously demonstrate nonresponse depressive symptom esketamine ketamine current major depressive episode , 4 oral antidepressant treatment option available doubleblind induction phase ( ie , duloxetine , escitalopram , sertraline , venlafaxine extend release [ XR ] ) current major depressive episode ( base MGHATRQ ) , adequate course treatment electroconvulsive therapy ( ECT ) current major depressive episode , define least 7 treatment unilateral/bilateral ECT Participant receive vagal nerve stimulation ( VNS ) receive deep brain stimulation ( DBS ) current episode depression Participant current prior DSM5 diagnosis psychotic disorder MDD psychosis , bipolar relate disorder ( confirm MINI ) , comorbid obsessive compulsive disorder , intellectual disability ( DSM5 diagnostic code 317 , 318.0 , 318.1 , 318.2 , 315.8 , 319 ) , borderline personality disorder , antisocial personality disorder , histrionic personality disorder , narcissistic personality disorder Participant homicidal ideation/intent , per investigator 's clinical judgment , suicidal ideation intent act within 6 month prior start screening/prospective observational phase , per investigator 's clinical judgment base Columbia Suicide Severity Rating Scale ( CSSRS ) Participants history moderate severe substance alcohol use disorder accord DSM5 criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Treatment-resistant Depression</keyword>
	<keyword>Esketamine</keyword>
	<keyword>Placebo</keyword>
	<keyword>Oral Antidepressant</keyword>
</DOC>